Educational information, not medical advice — ask your doctor or midwife.
Track Jumihaidokuto with reminders and record whether it helped, in the app.
Jumihaidokuto (十味敗毒湯) means roughly "ten-ingredient decoction to defeat toxin". It is a Kampo formula — that is, a Japanese adaptation of Chinese herbal medicine — devised in the late eighteenth century by the surgeon Hanaoka Seishu, who reworked the older Chinese formula Jingfang Baidusan for the skin and soft-tissue infections he saw in his practice.
The formula is built around bupleurum root, platycodon root and two "wind-dispelling" herbs, saposhnikovia and schizonepeta, with cherry bark (or oak bark, depending on the manufacturer), poria, cnidium, aralia, ginger and a small amount of licorice. In classical terms it is used for skin that is red, hot, itchy and prone to pus — boils, folliculitis, acne, weeping eczema, hives.
In modern Japan it is a routine prescription. It carries a national health-insurance listing, is stocked as standardised extract granules by the major Kampo manufacturers, and dermatologists prescribe it alone or alongside conventional treatment for acne and eczema. That everyday clinical use is real and long-standing. The formal trial evidence is much thinner: a small number of Japanese randomised and open-label studies, mostly modest in size, generally reporting improvement in acne lesion counts or eczema severity. It is reasonable to regard Jumihaidokuto as a plausible adjunct with a long track record, not as a proven treatment.
The mechanistic work is mostly laboratory and animal research rather than human physiology. Extracts of the formula have been shown in experimental models to dampen mast cell activation and histamine release, reduce neutrophil-driven inflammation, and modulate cytokine signalling in the skin — which would fit the traditional picture of an anti-itch, anti-pustule remedy. Individual herbs contribute plausibly: saikosaponins from bupleurum have anti-inflammatory activity, platycodin from kikyo is an expectorant and immunomodulator, and glycyrrhizin from licorice has a well-documented mild corticosteroid-like anti-inflammatory action. In Kampo theory the formula disperses "wind-heat" and drains "toxin" from the surface of the body. None of this has been confirmed as the mechanism of any clinical benefit in people.
By far the most common form is the freeze-dried decoction extract granule, sold as sachets by Tsumura (TJ-6), Kracie, Kotaro and others; these are standardised by manufacturing process and are what almost all the Japanese clinical data used. Tablets and capsules of the same extract exist and are easier to swallow but the granules remain the reference form. A traditional water decoction of the raw herbs is still made by some practitioners and is stronger-tasting but harder to dose consistently. Note that brands differ in one ingredient: Tsumura's version uses ouhi (cherry bark) while some others use bokusoku (oak bark). The licorice content is small but not negligible, and it is the same across brands.
The parent formula, Jingfang Baidusan, appears in Chinese texts of the Ming period as a treatment for externally contracted "wind-heat" with skin eruption. Hanaoka Seishu (1760–1835) — the surgeon best known for performing operations under a herbal general anaesthetic decades before Western ether — adapted it into Jumihaidokuto for suppurative skin and soft-tissue disease, and it entered the standard Kampo repertoire through his school. It has been continuously prescribed in Japan since, survived the Meiji-era suppression of traditional medicine, and was included when Kampo extract preparations were added to the Japanese national health insurance formulary in the 1970s. It remains one of the handful of formulas a Japanese dermatologist is likely to reach for.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.